Nukleiinhapete amplifikatsioonil põhinev diagnostika otse kliinilistest proovidest Chlamydia trachomatis detektsiooni näitel uriini proovist by Krõlov, Katrin
1
Tartu 2018
ISSN 2228-0855
ISBN 978-9949-77-639-9    
DISSERTATIONES 
TECHNOLOGIAE 
UNIVERSITATIS 
TARTUENSIS
43
K
A
T
R
IN
 K
R
Õ
L
O
V
 
N
ucleic acid am
plification from
 crude clinical sam
ples
KATRIN KRÕLOV
Nucleic acid amplification from
crude clinical samples  
exemplified by Chlamydia trachomatis  
detection in urine
DISSERTATIONES TECHNOLOGIAE UNIVERSATIS TARTUENSIS 
43 
 
 
 
 
 
  
DISSERTATIONES TECHNOLOGIAE UNIVERSATIS TARTUENSIS 
43 
 
 
 
 
 
KATRIN KRÕLOV 
 
 
 
 
 
 
 
 
 
  
 
Nucleic acid amplification from  
crude clinical samples  
exemplified by Chlamydia trachomatis  
detection in urine 
Institute of Technology, Faculty of Science and Technology, University of 
Tartu, Estonia 
 
This dissertation was accepted for the commencement of the degree of Doctor 
of Philosophy in biomedical technology on 22nd of November 2017 by the 
Council of the Institute of Technology, Faculty of Science and Technology, 
University of Tartu, Estonia. 
 
Supervisor: Prof. Ülo Langel 
Institute of Technology, University of Tartu, Estonia 
Chairman, Department of Neurochemistry, Stockholm 
University, Stocholm, Sweden 
 
Dr. Indrek Tulp 
Institute of Chemistry, University of Tartu, Estonia 
 
Opponent: Dr. Dirk Kuhlmeier, 
Fraunhofer Institute for Cell Therapy and Immunology IZI, 
Leipzig, Germany 
 
Commencement: Auditorium 121, Nooruse 1, Tartu, Estonia, at 13:15 on 
January 26th, 2018 
 
Publication of this dissertation is granted by the Institute of Technology, 
Faculty of Science and Technology, University of Tartu 
 
 
 
 
 
 
 
 
 
 
 
ISSN 2228-0855 
ISBN 978-9949-77-639-9 (print) 
ISBN 978-9949-77-640-5 (pdf) 
 
Copyright: Katrin Krõlov, 2018 
 
 
University of Tartu Press 
www.tyk.ee 
5 
ABSTRACT 
Sexually transmitted infections (STIs) have become a serious healthcare burden, 
with more than a million new cases acquired every day worldwide. The majo-
rity of STIs are asymptomatic, causing no discomfort to the patient, which 
further promotes their spread. Screening high-risk groups for STIs has been 
proven to be an effective strategy to restrict their spread. This requires support 
of efficient and fast diagnostics. Laboratory-based techniques offer a high level 
of diagnostic accuracy, but they are often time-consuming and require expen-
sive machinery and well-trained personnel. To date, the lack of cost-efficient, 
reliable point-of-care (POC) diagnostics has been considered the major barrier 
for STI control and prevention. Such tests could enable diagnosis and treatment 
within the same clinical visit. 
Chlamydia trachomatis is the most spread STI with 131 million new cases 
annually. Most POC tests for C. trachomatis diagnostics are based on immuno-
assay, with the major drawback of low sensitivity levels.  
The research presented in this thesis primarily addresses the issue of bring-
ing highly accurate and reliable nucleic acid-based diagnostics to POC applica-
tions. We have developed a recombinase polymerase isothermal nucleic acid 
amplification-based assay for specific C. trachomatis detection. The amplifica-
tion takes only 10 min to produce a naked-eye readable result using lateral-flow 
strip technology for product detection. The assay is highly sensitive and specific 
with 100% (95% CI, 70%–100%) clinical sensitivity and 100% (95% CI, 92%–
100%) specificity. 
Besides instrument-free application, one of the major advantages of iso-
thermal amplification is its higher tolerance towards biological sample compo-
nents. In our case, this enabled C. trachomatis target amplification directly from 
urine samples without prior nucleic acid extraction. The use of heat-treated 
urine samples for direct amplification resulted in 83% (95% CI, 51%–97%) cli-
nical sensitivity, which is significantly higher than the sensitivity of C. tracho-
matis immunoassays. The possibility of omitting the nucleic acid purification 
step is a great advantage for POC applications. However, two aspects must be 
considered when amplifying directly from clinical samples: biological specimen 
inhibition and sample pretreatment requirements. 
PCR is highly sensitive towards biological sample components, with inhibi-
tion of the reaction observed even when traces of the specimen remain in the 
extracted nucleic acid samples. We have found that loop-mediated isothermal 
amplification (LAMP) can tolerate the addition of up to 20% urine without 
significant impact on the amplification speed. We have also shown that high 
Na+ concentration is responsible for inhibition of urine samples on LAMP and 
that the inhibitory effect is mainly executed through affecting polymerase acti-
vity. Thus selection of more tolerant DNA polymerases is the most effective 
strategy to overcome clinical sample inhibition of the amplification reaction.  
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Sample pretreatment prior to downstream amplification is often required to 
release nucleic acid material from cells. We have compared the efficiency of 
different sample pretreatment strategies such as heat, alkali, detergent, and lyso-
zyme treatment. We have also introduced a novel sample pretreatment method 
using membrane-active antimicrobial peptides (AMPs). Our results showed that 
proper sample pretreatment can significantly increase downstream amplification 
efficiency, and AMP treatment worked best for E. coli detection from urine 
samples.  
In conclusion, this work explores the feasibility of nucleic acid amplification 
directly from clinical samples, presenting initial clinical efficiency data and 
addressing clinical sample inhibition and pretreatment issues.    
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INTRODUCTION 
Sexually transmitted infections are a major reproductive health concern world-
wide. Several STIs are associated with infertility, mother-to-child transmission, 
and adverse birth outcomes, in addition to the increased risk of HIV acquisition. 
Most prevalent STIs, such as Chlamydia trachomatis and Neisseria go-
norrhea, are effectively curable but require accurate and fast diagnosis, as they 
are majorly asymptomatic. While accurate diagnostics of the STIs and appro-
priate screening programs are widely used in high-income countries to address 
this health issue, low- and middle-income countries often lack access to afford-
able, time-efficient and geographically available diagnostics facilities. This is 
leading to low follow-up rates among patients and impeded treatment of the 
STIs, further promoting their spread.  
The availability of affordable rapid tests for infectious disease diagnostics is 
addressed by point-of-care (POC) diagnostics. In addition to being user-friendly 
and robust, rapid POC tests are required to be sensitive and specific, to gain an 
accurate diagnostic result, and preferably to be instrument-free. Application of 
POC tests for STI diagnostics is a way to restrict their spread and relieve their 
burden on the healthcare system.  
Currently, two STI tests meet these requirements: syphilis and HIV POC 
tests, which are both based on immunochromatographic antibody detection 
using lateral-flow technology. Although applicable in some cases, the majority 
of these tests fail to produce sensitivity and specificity that could meet labo-
ratory level diagnostics. Therefore, alternative methods are being explored for 
pathogen POC diagnostics.  
Nucleic acid amplification-based techniques (NAAT) are highly sensitive and 
specific methods that have been widely applied in laboratories. However, their 
application for POC purposes is restricted due to several requirements. The recent 
emergence of isothermal amplification techniques has enabled instrument-free 
performance of the NAAT, which is a major step towards POC applications. 
Still, several obstacles have yet to be overcome, such as sample processing and 
nucleic acid preparation prior to amplification. Direct amplification from mini-
mally processed or unprocessed clinical samples is one opportunity that is ad-
dressed in this thesis.   
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1. LITERATURE OVERVIEW 
1.1. Sexually transmitted infections 
There are more than 30 different bacteria, parasites, and viruses that are spread 
by sexual contact, causing over 1 million infections every day worldwide 
(WHO). The most prevalent sexually transmitted infections are Chlamydia 
trachomatis, Neisseria gonorrhoeae, Treponema pallidum (syphilis), and 
Trichomonas vaginalis. They are responsible for 357 million cases annually and 
are currently curable (WHO). However, bacteria resistance to antibiotics has in-
creased rapidly in recent years and reduced treatment options, particularly for 
Neisseria gonorrhoeae. Most prevalent incurable sexually transmitted infec-
tions are the hepatitis B virus (HBV), herpes simplex virus (HSV), human 
immunodeficiency virus (HIV), and human papillomavirus (HPV). HPV infec-
tion causes 0.5 million cases of cervical cancer and 0.27 million cervical cancer 
deaths annually (WHO). Effective and safe vaccines are currently available for 
HBV and HPV.  
The majority of STIs have no symptoms or display only mild symptoms, 
significantly inhibiting diagnosis and promoting their spread. In several cases, 
undiagnosed and uncured STIs can lead to serious reproductive health con-
sequences such as infertility in the case of Chlamydia trachomatis and Neisseria 
gonorrhoeae, mother-to-child transmission, and adverse birth outcomes. STI 
infections in pregnant women can lead to low birth weight and prematurity, 
stillbirth, neonatal death, pneumonia, sepsis, and neonatal conjunctivitis. In 
addition, several STIs, such as HSV and syphilis, can increase the risk of HIV 
acquisition. Thus, sexually transmitted infections are a major health concern 
worldwide. 
 
 
1.1.1. Epidemiology and pathology of  
Chlamydia trachomatis infection 
Chlamydia trachomatis can be considered the most prevalent sexually trans-
mitted infection worldwide. In 2012, the global estimates of C. trachomatis 
infections among women and men aged 15–49 years were 4.2% and 2.7%, 
respectively. These figures correspond to an estimated 131 million new cases of 
C. trachomatis annually (Newman et al., 2015).  
The estimated prevalence of C. trachomatis in Estonia is 6.9% and 2.7%, 
respectively, among women and men aged 18–35 years (Uusküla et al., 2008). 
C. trachomatis prevalence can be in particularly high among sexually active 
young adults. A study of 15–25 year old young adults (N=650) visiting Sexual 
Health Clinique in Tartu, Estonia in 2014 resulted in 14.9% and 11.7% C. 
trachomatis infection rates among women and men, respectively (Jevtuševskaja 
et al., 2016).  
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In most cases, C. trachomatis infection remains asymptomatic. It is estimated 
that 70–80% of women with C. trachomatis infection do not display any 
symptoms (Jevtuševskaja et al., 2016). However, in some cases, infection with C. 
trachomatis can result in acute salpingitis and pelvic inflammatory disease (PID), 
causing such long-term consequences as chronic pain, ectopic pregnancy, and 
infertility. In addition to sexual contact, C. trachomatis can be also transmitted 
from mother to newborn during vaginal delivery, causing conjunctivitis and 
pneumonia in the newborn. Ocular C. trachomatis can cause trachoma, the 
leading cause of blindness worldwide. Recent findings have also revealed a strong 
depletion of the p53 tumor suppressor during C. trachomatis infection, suggesting 
a potential pro-carcinogenic effect of the infection (González et al., 2014).  
C. trachomatis is divided into several serovars that are associated with diffe-
rent clinical manifestations. Serovars A-C are associated with eye infections 
causing conjunctivitis and trachoma. These infections are a major health con-
cern in remote areas of Africa and Asia (Taylor et al., 2014).  
C. trachomatis infection of the genital tract is generally caused by serovars 
D-K. These serovars can also cause conjunctivitis, pharyngitis, and pneumonia 
in newborns when transmitted perinatally (Darville, 2005).  
Whereas serovars A-K are generally confined to the mucosal epithelium, C. 
trachomatis lymphogranuloma venereum (LGV) serovars L1-L3 can cross the 
epithelium and spread to the lymphatics. LGV serovars are relatively rare in the 
U.S. and Europe but are particularly prevalent in tropical and subtropical areas 
of developing countries.  
C. trachomatis infection can be treated with antibiotics such as zithromycin 
or doxycycline. The infection can also be cleared spontaneously in the absence 
of treatment as a consequence of adaptive and innate immune responses 
(Geisler, 2010).  
C. trachomatis infect epithelial cells of the urogenital tract and conjunctiva. 
Epithelial host cells are the primary initiators and propagators of the host im-
mune response to C. trachomatis infection. Infected epithelial cells secrete 
chemokines and cytokines, recruiting inflammatory leukocytes to the site of 
infection and inducing cellular inflammatory response. These mediators induce 
direct damage to the host epithelial tissue, causing scarring of the tissue that 
ultimately leads to inflammatory pathologic conditions like PID, particularly 
upon repeated infections (Darville and Hiltke, 2010).  
 
 
1.1.2. Microbiology and molecular biology of C. trachomatis 
C. trachomatis is an obligate intracellular Gram-negative bacterial pathogen. C. 
trachomatis has a biphasic developmental cycle. A small and metabolically 
inactive elementary body attaches and enters epithelial cells. In the host cell, it 
transfers to a larger metabolically active reticulate body that replicates by binary 
fission. Prior to host-cell lysis and release, the reticulate bodies transform into 
the elementary bodies.  
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C. trachomatis has a 1Mbp chromosome and a multicopy 7.5kb plasmid 
(Zhong, 2017). Although the plasmid is not required for C. trachomatis growth 
in vitro, it has been shown to be an important virulence factor required for 
induction of genital tract infection in mouse models (O'Connell et al., 2007, 
Farencena et al., 1997). C. trachomatis cells carry on average 4–10 copies of the 
cryptic plasmid, depending on the strain and development cycle stage (Pickett et 
al., 2005, Seth-Smith et al., 2009).  
The plasmid encodes eight open reading frames or plasmid glycoproteins 
pGP1-8 (Zhong, 2017). Sequence homology data indicated that pGP7 and pGP8 
are probably involved in plasmid replication and pGP1 is homologous to 
double-stranded DNA helicase. Sequence data also showed that pGP5 and 
pGP6 could be involved in regulating plasmid copy number and partitioning 
(Thomas et al., 1997). Deletion analysis showed that pGP1, pGP2, pGP6, and 
pGP8 are important for plasmid maintenance (Gong et al., 2013, Liu et al., 
2014a, Song et al., 2013). pGP3 is a major factor involved in plasmid-depend-
ent pathogenicity and induction of host inflammatory response (Liu et al., 
2014b, Ramsey et al., 2014). pGP4 is a transcriptional regulator of pGP3 and 
several chromosomal genes, like glycogen synthase glgA, which is likely to be 
important for chlamydial virulence (Song et al., 2013). pGP5 is a negative 
regulator for several plasmid-dependent genes (Liu et al., 2014a). Thus, pGP4 
and pGP5 are probably involved in chlamydial adaptation to various animal 
tissue environments.  
 
 
1.2. Molecular diagnostics of C. trachomatis 
Several STIs are considered to be majorly asymptomatic, including Chlamydia 
trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma 
hominis, Ureaplasma sp. (Ona et al., 2016, Takahashi et al., 2006). The lack of 
correlation between symptoms and these STI infections makes them difficult to 
diagnose based on clinical observation. Routine screening of high-risk groups 
could control the spread of these infections and prevent their long-term con-
sequences, such as infertility and PID. This requires the support of accurate and 
time-efficient diagnostics.  
Several different molecular diagnostics techniques are applied for specific 
pathogen detection. In general, C. trachomatis can be diagnosed using culture, 
nucleic acid amplification techniques (NAAT), or immumoassays, which are 
explained below. 
 
 
1.2.1. Specimen type and collection for  
C. trachomatis diagnostics 
The accuracy of the diagnostic test is highly affected by specimen quality. Seve-
ral sources have reported reduced sensitivity due to inappropriate specimen 
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collection or transportation. Culture-based and other diagnostics methods focu-
sing on detection of live pathogens are particularly sensitive towards specimen 
collection and handling, causing an up to 30% reduction in sensitivity due to 
inadequate specimens (Black, 1997).  
Several sample types have been used for STI diagnostics, including urine, 
semen, swab, and tissue samples from relevant anatomical sites. To date, the 
FDA has approved the use of urine, female vaginal and endocervical swabs, and 
male urethral swabs for C. trachomatis detection (Prevention, 2014).  
Specimens with less invasive collection types are preferred, and self-col-
lected vaginal swabs and urine samples are accepted for STI diagnostics. Urine 
specimens are accepted by all FDA accredited NAAT-based diagnostics 
methods. In addition to their non-invasive and self-collected nature, urine 
samples tolerate prolonged storage at RT°C (Prevention, 2014). Until recently, 
first void urine (FVU) samples were accepted for C. trachomatis diagnostics 
only in males. Now urine specimens are accepted for STI diagnostics for both 
males and females, and no timing of specimen collection is required, with 
midstream urine proven acceptable for NAAT diagnostics of C. trachomatis 
(Mangin et al., 2012, Prevention, 2014). 
 
 
1.2.2. Culture-based techniques  
for C. trachomatis diagnostics 
C. trachomatis culture detects viable infectious organisms. The culture is per-
formed by inoculating a cell culture monolayer (e.g. HeLa 229) with patient 
swab specimens. If sufficiently viable C. trachomatis is present in the sample, it 
will infect the cells and the intracytoplasmic inclusions will be observed after 
48–72 h. Gram, Giemsa, or iodine staining can be used; however, these stains 
are less suitable for specific chlamydial inclusion detection, and fluorescently 
labeled antibodies are better to apply. The antibodies target chlamydial lipo-
polysaccharide (LPS) to recognize all chlamydial species or major outer 
membrane proteins (MOMP) for specific C. trachomatis detection. Sonication 
is often applied prior to inoculation to disrupt intracellular inclusion bodies and 
separate elementary bodies (Black, 1997).  
C. trachomatis culture was considered the gold standard more than 20 years 
ago. The culture method is 100% specific and is still applied in some cases 
where high specificity is required or when a viable organism needs to be ob-
tained for further studies, such as antibiotics susceptibility or genotyping. 
Another advantage of culture methods is their low contamination rate.  
The clinical sensitivity of the culture is at best 60–80% that of NAAT and 
depends highly on the experience of the technicians performing the procedure 
(Figure 1) (Meyer, 2016). Culture-based methods have stringent sample col-
lection and transport requirements in order to preserve viable C. trachomatis. 
The other factors commonly affecting culture sensitivity are toxic substances 
present in clinical specimens and overgrowth of the cell culture by commensal 
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microorganisms. Availability of the C. trachomatis culture is also considered 
limited to clinicians due to its expense, the high level of technical expertise 
required, and lengthy turn-around time (3–7 days) (Black, 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Relative sensitivity and specificity of techniques used to diagnose C. tracho-
matis (Meyer, 2016). Sensitivity is described as the minimum number of bacteria 
detected by the test. Highly sensitive tests require less pathogen for detection. The 
pathogen amount in the sample during acute (primary) and persistent (longer lasting) 
infections is also indicated. EIA – Enzyme Immunoassay; DFA – Direct 
Immunofluorescence Assay; NAAT – nucleic acid amplification techniques.  
 
 
1.2.3. NAAT-based tests for C. trachomatis diagnostics 
Nucleic acid amplification-based techniques are very sensitive and specific 
methods and are therefore considered a new gold standard for several pathogen 
diagnostics, including C. trachomatis. In contrast to culture, NAAT tests do not 
depend on viable pathogens; therefore, they have less stringent sample type, 
collection, and handling requirements. Furthermore, due to improvements to 
NAAT, less invasive sample types can be used for pathogen diagnostics. Due to 
the high sensitivity of NAAT, contamination caused by product carryover can 
be a problem, though.  
Polymerase chain reaction (PCR) is the most common NAAT. It has been 
applied for C. trachomatis detection since 1993 and is still applicable in several 
FDA-approved methods, such as Abbott RealTime, Cepheid Expert, and 
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Amplicor CT/NG tests (Table 1). Most of the PCR-based NAAT use fluores-
cently labelled oligonucleotide probes for specific amplification product detec-
tion. NAAT assays offer high sensitivity, usually well above 90%, and speci-
ficity of ≥ 99% (Figure 1).  
 
 
Table 1. FDA approved NAAT tests for C. trachomatis diagnostics (Prevention, 2014) 
Test name (manufacturer) NAAT Amplification target 
Abbott RealTime CT/NG  
(Abbott Molecular Inc.) PCR  
Two distinct regions of the cryptic 
plasmid 
BD ProbeTec ET and Qx assays  
(Becton Dickinson) SDA Cryptic plasmid target 
Xpert CT/NG assay  
(Cepheid) PCR Chromosomal region  
Aptima COMBO 2 assay 
(Hologic) TMA 23S rRNA 
Amplicor and cobas CT/NG test  
(Roche Molecular Diagnostics) PCR 
Cryptic plasmid and chromosomal 
target 
 
 
Cryptic plasmid is a commonly used target for C. trachomatis NAAT, as it is 
present in several copies per cell. rRNA genes are also used for NAAT assays, 
as they may be present in up to 15 copies per bacterial genome (Klappenbach et 
al., 2001). However, rRNA genes can be relatively conserved among closely 
related species, possibly affecting specificity levels of the assay.  
As an intracellular pathogen, C. trachomatis is considered to be highly con-
served and genetically stable. However, in 2006, a 377 bp deletion of the cryp-
tic plasmid coding sequence 1 (CDS1) region was discovered in Sweden (and is 
known as the Swedish variant) (Unemo and Clarke, 2011). The deletion over-
lapped with the C. trachomatis single target NAAT assays used by Abbot and 
Roche diagnostics systems at the time. This caused rapid spread of the Swedish 
variant due to thousands of false negative diagnoses. Since then, dual-targeting 
has often been applied with an additional chromosomal target (ompA). The 
Swedish variant case stresses the importance of target selection for NAAT diag-
nostics assays.  
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1.2.4. Non-culture, non-NAAT tests for  
C. trachomatis detection 
Other diagnostics tests for C. trachomatis include antigen-based detection 
methods (DFA, EIA), DNA probe assays, and serological tests.  
DFA (Direct Immunofluorescence Assay) is based on direct microscopic 
visualization of specimens by staining with a C. trachomatis-specific fluores-
cent antibody. MOMP- and LPS-targeting antibodies are often used. DFA tests 
have high specificity but are generally less sensitive than culture-based methods 
(Figure 1) (Black, 1997). In addition, although DFA staining is rapid, micro-
scopic evaluation of each sample is laborious and requires highly experienced 
personnel.  
EIA (Enzyme Immunoassay) is based on immunochemical detection of chla-
mydial LPS with enzyme-linked antibodies. The product of the enzymatic re-
action, after specific antibody binding to the antigen, is then detected with a 
spectrophotometer or fluorescence reader. LPS is often used in EIA as an anti-
gen since it is more abundant and soluble than MOMP. Although LPS is con-
sidered a genus-specific antigen, some cross-reactivity with other Gram-nega-
tive bacteria has been observed (Haralambieva et al., 2001). Some EIAs also do 
not differentiate between different chlamydia species (Jones et al., 2003). Thus, 
relatively low specificity is a problem for EIA (Figure 1).  
C. trachomatis can also be detected by hybridization of the DNA probe to 
the unamplified genomic DNA. The test uses a chemiluminescent DNA probe, 
which hybridizes to a chlamydia-specific sequence of the 16S rRNA. DNA-
rRNA hybrid produces a luminometer-detectable chemiluminescent response. 
Actively dividing C. trachomatis contain up to 104 copies of 16S rRNA; thus, 
DNA probe assay has higher sensitivity than EIA (81% and 50% respectively, 
as compared to NAAT) (Figure 1) (Lauderdale et al., 1999). DFA, EIA, and 
DNA probe hybridization tests are no longer recommended for routine C. 
trachomatis diagnostics due to their insufficient accuracy (Figure 1) (Pre-
vention, 2014).  
Serological tests are generally not useful for C. trachomatis detection, as the 
antibody response becomes detectable only after several weeks, and antibody 
titers may be low. Additionally, antibodies elicited by the infection are long 
lived and a positive test will not distinguish between previous and current in-
fections. Although serology is considered to be helpful in some cases of chronic 
infections with low pathogen counts and for diagnostics of LGV serovar infec-
tions due to stronger antibody responses of the systemic disease, it is not widely 
applied (Meyer, 2016, Black, 1997).  
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1.3. Point-of-care (POC) diagnostics 
Globally, control of curable STIs is increasingly focusing on point-of-care tools. 
POC tests can be defined in multiple ways. Generally, any diagnostic tool that 
can provide accurate results and facilitate treatment within the same clinical 
visit is considered POC applicable. However, POC test requirements are often 
designed based on the ASSURED criteria: Affordable, Sensitive, Specific, 
User-friendly, Rapid and robust, Equipment-free, and Deliverable to end-users.  
The purpose of POC testing is to reduce the time-to-result, allowing STI 
diagnosis to be made within the same visit to the doctor. This is particularly 
important in resource-poor environments where low patient follow-up rates are 
reported, as patients are often unable to return to the clinic to receive the appro-
priate treatment (Schwebke et al., 1997). This causes the spread of infection to 
sex partners, transmission from mother to child, and serious health con-
sequences for patients. Syndromic management of STIs is majorly inapplicable 
due to the asymptomatic nature of most infections and can lead to inappropriate 
treatment, contributing to the growing global problem of antibiotic resistance. 
Therefore, appropriate POC testing is required to control the spread and health 
issues resulting from STIs.  
In addition to reducing time to treatment, POC offers also a cost-efficient 
strategy for large-scale screenings and is often the only possibility for appro-
priate diagnostics in resource-constrained regions, where electricity, pure water, 
or skilled personnel are simply unavailable.  
Most of the POC tests are immunochromatographic assays that detect patho-
gen antigens using lateral-flow technology. However, poor accuracy of these 
tests is a concern that has limited their wider application (Figure 1). Currently, 
only HIV and syphilis POC tests have been accepted for diagnostics applica-
tions, while others struggle to produce sensitivity and specificity that meets the 
laboratory level diagnostics of the STI.  
The OraQuick POC test for HIV detection at home was approved by the 
FDA in 2012. The test detects HIV-1 and HIV-2 antibodies from oral swab in 
20 min with 93% sensitivity and close to 100% specificity (Tucker et al., 2013). 
Several Treponema palladium antibody tests from whole blood, serum, or 
plasma are available for fast syphilis diagnostics. The sensitivity of the syphilis 
POC tests from whole blood ranges from 86.3 to 100%, and their specificity is 
in the range of 95.9%–97.0% (Cristillo et al., 2017).  
 
 
1.3.1. POC diagnostics of C. trachomatis 
Several assays for C. trachomatis detection are considered POC applicable, 
although none of them can currently fully meet the ASSURED criteria.  
Gram staining of urethral smears is a quick assay that involves microscopic 
evaluation of stained urethral samples. Large-scale evaluation involving 26,000 
male patients has shown relatively good sensitivity values of 91.0% for sympto-
20 
matic male patients and 83.8% for all male patients irrespective of symptoms 
(Table 2) (Bartelsman et al., 2015). However, method specificity values were 
poor at 53.1% and 74.1%, respectively (Table 2) (Bartelsman et al., 2015). 
Additionally, Gram staining has been criticized due to its uncomfortable/painful 
sample collection, the requirement of skilled personnel for microscopic evalua-
tion, and poor consistency of results (Apoola et al., 2011, Smith et al., 2003).  
Urine flow cytometry could potentially be applied, as increased white cell 
counts in first void urine samples have been observed for C. trachomatis-in-
fected patients. Although the test has relatively good sensitivity (93.7%), it fails 
to distinguish C. trachomatis and Mycoplasma genitalium infections, which 
have different treatment profiles (Table 2) (Pond et al., 2015). Due to the robust 
and rapid nature of the test, it could be useful for the pre-screening purposes.  
The Handilab C test detects the C. trachomatis-specific enzyme Peptidase 
123A. The test is rapid and robust, does not require additional instrumentation, 
and therefore meets several POC criteria. However, its sensitivity is quite poor 
(22.5%) (Table 2) (van Dommelen et al., 2010).  
The majority of the C. trachomatis POC assays to date are immune 
chromatographic tests based on lateral-flow-technology that detect chlamydia-
specific LPS antigen in a biological sample. The Biorapid, ACON, and Quick-
Vue C. trachomatis tests are applicable in POC settings and have relatively high 
specificity levels (Table 2) (Nuñez-Forero et al., 2016, Hurly et al., 2014, van 
Dommelen et al., 2010). However, the sensitivity of the immunochromato-
graphic tests remains in the low range of 20–40% according to large-scale 
studies (Table 2) (van Dommelen et al., 2010, Nuñez-Forero et al., 2016).  
Attempts have been made to increase antigen-based assay sensitivity. In the 
newly developed aQcare assay, europium-chelated nanoparticles and a time-
resolved fluorescence (TRF) reading system were applied for more accurate 
results. The aQcare system requires a small portable signal-acquisition device 
for application and has shown a significantly increased sensitivity levels com-
pared to ACON and QuickVue assays (Table 2) (Ham et al., 2015). However, 
additional evaluation by other research groups is required to support this data.  
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A signal amplification system (SAS) is another technology used to increase 
immunoassay sensitivity by applying a multiple hapten-labelled antibody for 
stronger visual signal when detecting a protein target (applied by the Diagnos-
tics for the Real World). The test has shown somewhat increased sensitivity; 
however, clinical evaluation results are quite variable and depend on the sample 
type (Table 2) (van der Helm et al., 2012, Hurly et al., 2014). Therefore, the 
effect SAS technology on the clinical performance of the immunoassay is un-
clear.  
Cepheid employed NAAT in a fully automated system that enables pathogen 
detection within 90 min. The GeneXpert system uses cartridges that combine 
on-board sample preparation with real-time PCR. Cepheid GeneXpert has 
sensitivity and specificity that meet laboratory level NAAT diagnostics and is 
applicable with different sample types (Table 2) (Gaydos et al., 2013). How-
ever, the analysis requires the use of thermal and optical module instrumenta-
tion. 
To conclude, to date there is no test for C. trachomatis detection that meets 
all ASSURED criteria. Immunochromatography-based tests are very fast, 
robust, affordable, and instrument free; however, their sensitivity levels in 
clinical evaluations are poor. Automated systems with NAAT-based detection 
offer excellent clinical performance levels but require use of appropriate 
instrumentation. The speed and affordability of these tests are also questionable 
in terms of POC application. Therefore, new strategies must be explored with 
one opportunity being the use of isothermal NAAT. These are more robust and 
faster and have less stringent instrumentation requirements than PCR and could 
potentially offer laboratory level sensitivity.  
 
 
1.4. Isothermal nucleic acid amplification  
Isothermal techniques enable nucleic acid amplification at constant tempera-
tures and therefore do not require temperature cycling as conventional PCR 
does. Therefore, isothermal amplifications have strong advantages for POC 
applications. Since emerging in the 1990s, several methods have been deve-
loped that can be classified into four categories (Niemz et al., 2011): 
 
 RNA transcription-based (NASBA, TMA) 
 DNA replication-based with enzymatic duplex melting/primer annealing 
(HDA, RPA) 
 DNA polymerase-mediated strand displacement-based methods form 
linear or circular targets (RCA, LAMP) 
 Polymerase extension/strand displacement-based plus single strand 
cutting event (SDA, NEAR) 
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Nucleic acid sequence-based amplification (NASBA) and transcription-
mediated amplification (TMA) use a retroviral strategy for RNA replication 
via cDNA intermediate (Figure 2a) (Compton, 1991). These methods are 
particularly useful for RNA virus diagnostics. They use two sequence-specific 
primers, reverse transcriptase, DNA dependent RNA polymerase, and in some 
cases RNase H. Although reaction is performed at 41°C, it does require a 65°C 
preheating step for initial primer annealing (Compton, 1991).  
Helicase-dependent amplification (HDA) mimics DNA replication fork 
and uses helicase to separate double-stranded DNA (Figure 2b) (Vincent et al., 
2004). Originally, HDA used E. coli UvrD helicase, SSB protein to prevent 
unwound DNA from re-annealing and DNA polymerase I Klenow fragments. 
The reaction can be successfully performed with the use of two primers at 37°C. 
Recombinase polymerase amplification (RPA) uses recombinase to introduce 
primers to the template strand, SSB to stabilize ssDNA structures formed during 
amplification, and a DNA polymerase with strand-displacement activity (Bacil-
lus subtilis Pol I, Bsu) (Figure 2b) (Piepenburg et al., 2006). RPA reaction is 
performed at 37°C–42°C.  
Rolling circle amplification (RCA) employs a rolling circle mechanism 
used for replication of plasmids and viral genomes. RCA uses highly processive 
DNA polymerase from Phi29 bacteriophage to synthesize multiple repetitions 
of the circular template (Figure 2c) (Fire and Xu, 1995). Loop-mediated iso-
thermal amplification (LAMP) is another method using strand displacement 
and cyclic amplification (Figure 2c). LAMP reaction is performed at around 
63°C because at this temperature dsDNA is in a dynamic equilibrium state that 
allows primers to anneal to the template without the denaturation step. LAMP 
reaction is initiated with a non-cycling amplification step that results in a single-
stranded double stem–loop DNA structure or dumbbell structure (Notomi et al., 
2000). The latter allows the reaction to enter the cycling amplification, resulting 
in a high molecular weight product. LAMP uses four primers, although two 
additional loop primers can be added to increase the sensitivity or speed of the 
reaction (Nagamine et al., 2002).  
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Figure 2. Overview of isothermal nucleic acid amplification reactions (modified 
from (Niemz et al., 2011). (a) Methods based on RNA; (b) Methods based on DNA 
replication with enzymatic duplex melting/primer annealing; (c) Methods based on 
strand-displacing polymerization from linear or circular targets; (d) Methods based on a 
polymerase extension and a single-strand cutting event.  
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Strand displacement amplification (SDA) uses a restriction endonuclease to 
nick the target DNA strand and exonuclease-deficient DNA polymerase to dis-
place DNA strand from the nick site (Figure 2d) (Hellyer and Nadeau, 2004). 
Phosphothioates are incorporated into the amplicon during amplification so that 
the endonuclease only cuts one strand. SDA requires an initial denaturation 
step, but the rest of the reaction is performed at 37°C. Nicking enzyme amplifi-
cation reaction (NEAR) uses the single-strand nicking endonuclease N.BstNB 
and therefore does not require modification of the amplicon strand (Figure 2d) 
(Morgan et al., 2000). Additionally, NEAR uses thermophilic enzymes that 
allow forgoing the initial denaturation step, and the reaction can be performed 
as a single-step procedure at 54–60°C.  
Several isothermal amplification techniques have been applied commercially 
for STI diagnostics. Hologic uses a TMA-based system that can be employed 
for C. trachomatis, N. gonorrhoeae, Trichomonas vaginalis, Mycoplasma geni-
talium, Zika virus, HBV, HCV, HSV, HIV and HPV diagnostics. bioMérieux 
implement NASBA and Becton Dickins SDA for nucleic acid-based diag-
nostics. RPA is commercialized by TwistDX, which currently offers several 
food-borne pathogen detection kits. Eiken’s LAMP-based Loopamp technology 
is applied for several food and environmental pathogen-detection purposes as 
well as Mycobacterium tuberculosis and Plasmodium species detection for 
tuberculosis and malaria diagnostics, respectively.  
 
 
  1.4.1. Loop-mediated isothermal amplification (LAMP) 
LAMP was developed in 2000 and remains the most widely applied isothermal 
amplification technique to date. LAMP is a highly efficient and specific ampli-
fication, its primers recognizing six distinct regions in the target DNA. How-
ever, non-template amplification (amplification of primers without template 
DNA) can be a concern, particularly with multiplexed reactions, and non-
specific amplification can be observed upon prolonged incubation (Tanner et 
al., 2012, Francois et al., 2011).  
During LAMP reaction, a large amount of DNA is synthesized that has a 
ladder-like appearance on the agarose gel. This is a unique feature of LAMP, as 
reaction results can be evaluated by the naked eye due to formation of white 
turbidity by magnesium ions and pyrophosphates (Mori et al., 2001). In addi-
tion, a fluorescent metal indicator, like calcein, can be added to the reaction, 
generating substantial naked-eye visible change in the fluorescence upon pro-
duct formation (Tomita et al., 2008), a great advantage for POC applications.  
Because of the aforementioned characteristics, LAMP has been widely 
applied for end-point as well as real-time detection of pathogen RNA/DNA, 
including bacteria (Hanaki et al., 2011, Wang et al., 2011, Su et al., 2014, 
Kaewphinit et al., 2013, Gelaw et al., 2017), viruses (Kumvongpin et al., 2017, 
Singleton et al., 2014, Priye et al., 2017, Wang et al., 2016, Ge et al., 2013), 
fungi (Inácio et al., 2008), protozoan parasites (Yongkiettrakul et al., 2014, 
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Adao and Rivera, 2016), and nematodes (Mugambi et al., 2015). LAMP has 
also been applied for genetically modified material identification (Xu et al., 
2013), SNP analysis (Lu et al., 2017, Zhang et al., 2016), gene copy number 
discrimination (Nakamura et al., 2010), and RNA expression analysis (Muto et 
al., 2011).  
Due to the principle of oligonucleotide annealing, LAMP has relatively 
stringent incubation temperature requirements and needs incubation within 57–
67°C for assay performance (Francois et al., 2011).  
Several options have been investigated for instrument-free POC application 
of LAMP, including electricity-free heaters based on exothermic chemical re-
actions and appropriate phase change materials for successful incubation 
(LaBarre et al., 2011). Disposable pocket warmers have been applied as a heat 
source required for reaction (Hatano et al., 2010, Hatano et al., 2011).  
 
 
1.4.2. Recombinase polymerase isothermal amplification (RPA) 
RPA is a relatively new method that relies on an enzymatically driven primer 
binding process rather than the physio-chemical dependent hybridization used 
in LAMP. For that reason, RPA can tolerate ambient reaction temperatures 
(31°C–43°C) and can therefore be applied with a simple non-instrumented heat 
source such as a chemical heater, allowing lowering of the ambient temperature 
as low as 10°C (Lillis et al., 2014). This makes RPA a particularly attractive 
candidate for POC applications. However, for optimal reaction time and sensiti-
vity, RPA temperatures should be kept at 37–42°C (Figure 3), at which reaction 
time required to result can be 3–12 min depending on the template amount 
(Wang et al., 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. RPA reaction time dependence on incubation temperature at template 
concentrations near LOD (based on data obtained from TwistDX, (Lillis et al., 2014, 
Wang et al., 2017). Required reaction time for product formation is plotted against 
reaction temperature.  
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RPA reaction uses crowding agents like high molecular weight polyethylene 
glycol (PEG) to improve amplification efficiency. However, due to the viscous 
nature and relatively low amplification temperature of PEG, localized depletion 
of the amplification reagents occurs, restraining amplification cascade. Thus, a 
mixing step after 3–6 min of incubation is required for optimal performance of 
RPA (Lillis et al., 2016).  
RPA is also an attractive candidate for POC applications because its reagents 
are supplied in a lyophilized form and are relatively stable, with no reduction of 
the assay performance after 12 weeks’ storage at 25°C and 6 weeks’ storage at 
45°C (Lillis et al., 2016).  
 
 
1.5. Clinical sample preparation prior  
to nucleic acid amplification 
A major obstacle for instrument-free NAAT application for POC diagnostics is 
the requirement of biological sample preparation prior to amplification. Nucleic 
acid purification is widely applied in the laboratory settings, as it enables 
extraction of DNA/RNA from cellular material and eliminates the majority of 
amplification inhibitors. Although some attempts have been made in the form of 
single-use sample-prep devices, sample preparation remains an unresolved issue 
in POC diagnostics.  
 
 
1.5.1. Biological sample substances associated  
with NAAT inhibition  
Biological sample inhibitors are a major concern for molecular diagnostics, signi-
ficantly affecting downstream amplification efficiency, increasing false-negative 
results, and causing loss in sensitivity and accuracy of diagnostic assays.  
Studies have shown that 7% and 11.9% of urine samples were inhibitory for 
PCR and TMA, respectively. PCR inhibition was associated with beta-human 
chorionic gonadotropin (beta-HCG) and salt crystals. TMA inhibition was due 
to hemoglobin, nitrites, and crystals (Mahony et al., 1998). Urea has also been 
known to inhibit PCR reaction at concentrations of 50 mM and above (Khan et 
al., 1991), possibly due to denaturation of the polymerase (Wilson, 1997, 
Schrader et al., 2012).  
The presence of blood significantly inhibits PCR, as Taq DNA polymerase 
can tolerate 0.2% or less blood in the reaction (Abu Al-Soud and Rådström, 
2000, Abu Al-Soud and Râdström, 1998). Plasma, immunoglobulin G, hemo-
globin, heparin, and lactoferrin are major proposed inhibitors of blood samples 
(Al-Soud and Rådström, 2001, Al-Soud et al., 2000, Wilson, 1997).  
Amplification inhibitors can interfere with DNA polymerase by directly 
binding and blocking enzyme activity. Inhibitors may also target DNA poly-
merase cofactor requirements, acting by reducing Mg2+ availability or inter-
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fering with Mg2+ binding by the DNA polymerase. Several inhibitors interact 
with template DNA, preventing amplification and causing co-purification of the 
inhibitors. Protease and nuclease activity of the biological sample can also 
contribute to the reduced amplification efficiency (Wilson, 1997, Schrader et 
al., 2012).  
 
 
1.5.2. Different sample preparation techniques  
applied prior to NAAT  
Nucleic acid purification is the most efficient and most commonly applied 
method for amplification inhibitor removal. Purification is easy to apply in 
laboratory settings, but its cost and technical challenge make it difficult to apply 
in POC conditions. Therefore, several alternative sample preparation techniques 
have been applied that target two purposes: (i) increasing target DNA available 
for amplification through disruption of the cellular material and (ii) overcoming 
the inhibitory effect of crude biological samples.  
Addition of bovine serum albumin (BSA), betaine, ssDNA binding protein 
(SSB) from T4 bacteriophage, or a protease inhibitors cocktail can partially 
reduce PCR blood inhibition. These additions allow Taq DNA polymerase to 
tolerate up to ten times more whole blood (up to 2%) in the PCR reaction 
(Kreader, 1996, Topal and Sinha, 1983, Forbes and Hicks, 1996). Heating, 
freeze-thawing, and diluting the sample can also increase amplification effi-
ciency, as can activated carbon treatment (Mahony et al., 1998, Schrader et al., 
2012, Verkooyen et al., 1996). Addition of mild detergents (such as Tween 20), 
DTT, DMSO, ß-mercaptoethanol, or PEG can also potentially reduce the action 
of the inhibitory substances (Schrader et al., 2012).  
One of the proposed mechanisms for removal of the urine sample inhibitory 
substances is freeze-thawing, or overnight storage at either 4°C or –70°C. 42% 
and 79% of urine samples lost their inhibitory effect in PCR and TMA, respecti-
vely, after overnight storage at 4°C. –70°C storage further increased the loss of 
the inhibitory effect in 58% of PCR samples (Mahony et al., 1998). The mecha-
nism of the inhibition loss is unclear, but deactivation of the labile protei-
naceous inhibitors has been proposed through inducing their conformational 
change leading to subsequent loss of activity (Mahony et al., 1998). Alterna-
tively, this effect might also be due to release of additional target nucleic acid 
molecules by disrupting microbial cells.  
One of the most efficient strategies for amplification inhibition reduction is 
genetic manipulation of the DNA polymerase. Deletion of the N-terminal 
portion from Taq polymerase increases its blood tolerance by 10–100 times 
(Kermekchiev et al., 2009). Additional single amino acid mutation further 
enhances Taq tolerance towards several biological samples and inhibitors, such 
as blood, hemoglobin, lactoferrin, plasma, serum IgG, soil extracts, humic acid, 
and even DNA intercalating dyes (Kermekchiev et al., 2009). The mechanism 
of blood sample inhibition has been shown to be predominantly related to 
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reduction of DNA polymerase extension speed (Kermekchiev et al., 2009). 
Other researchers have also achieved increased tolerance towards several inhi-
bitors such as heparin, humic acid, peat extract, coprolite, clay-rich soil, cave 
sediment, and tar by genetically modified Taq polymerase variants or chimeras 
(Ghadessy et al., 2001, Baar et al., 2011). Therefore, the choice of DNA poly-
merase has a crucial role in amplification efficiency (Wiedbrauk et al., 1995, 
Abu Al-Soud and Râdström, 1998).  
While the issue of biological sample-associated inhibitors is mainly 
addressed by amplification buffer composition and DNA polymerase mani-
pulation, several sample preparation strategies are applied for the purpose of 
nucleic acid release from cellular material. Sample preparation can be divided 
into four categories: (i) mechanical lysis, (ii) thermal treatment, (iii) enzymatic 
lysis, and (iv) chemical lysis.  
Biological sample material can be prepared mechanically using beads mills, 
electrical treatment, ultrasonication, or simple freeze-thawing procedure. A 
major advantage of the mechanical treatment is its robustness and lack of inhi-
bition to the downstream amplification procedure. Although attempts have been 
made to apply mechanical treatment in an instrument-free way, it remains 
difficult (Gabardo et al., 2015). 
Heating is the most widely applied crude sample preparation procedure. It is 
simple, fast, and applicable to several biological sample types, such as blood 
and saliva (Poon et al., 2006, Nakanishi et al., 2011, Modak et al., 2016, Nyan 
et al., 2014). Boiling has been proven to be the best sample pretreatment pro-
cedure over detergent, Proteinase K, and alkali treatment for nasopharyngeal 
samples (Nie et al., 2012, Sun et al., 2014). However, thermal treatment is chal-
lenging to apply in POC settings due to high-temperature requirements.  
Enzymatic lysis facilitates the release of nucleic acid material using bacte-
riolytic or proteolytic enzymes such as Proteinase K, lysozyme, PlyC, or muta-
nolysin. Proteinase K treatment has been applied for simulated sputum, urine, 
and serum samples spiked with Zika virus, for which it proved superior to heat 
and alkali treatment and was just as efficient as DNA extraction (Wang et al., 
2016). Proteinase K has also been applied for nasopharyngeal sample treatment; 
however, boiling was more efficient for this sample type (Nie et al., 2012). 
Mutanolysin treatment has been applied for saliva samples (Nakanishi et al., 
2011). PlyC lysin from the streptococcal bacteriophage was efficiently applied 
for Gram-positive Streptococci species (Nelson et al., 2006). Use of lysozyme is 
complicated by the additional requirement for favorable osmotic conditions and 
the sensitivity of its lysis activity towards different buffer conditions (Sedov et 
al., 2011). Thus, Gram-negative bacteria lysis with lysozyme requires addition 
of the Triton X-100 or EDTA for sufficient efficiency (Voss, 1964).  
Chemical lysis includes alkali and mild detergent treatments. Alkaline lysis 
has been efficiently applied for nucleic acid extraction from blood sample, but 
sputum, urine, and other sample materials could also be suitable (Zhang et al., 
1992, Rudbeck and Dissing, 1998, Wang et al., 2016). Several detergents can 
efficiently lyse cellular membranes. However, the majority of them are highly 
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inhibitory for downstream amplification due to their protein denaturing pro-
perties. Nonionic detergents such as Triton X-100 and octylthioglucoside are 
often applied for bacterial cell lysis (Schilling et al., 2002, Abolmaaty et al., 
2000). Triton X-100 treatment was successfully applied for protozoan Plas-
modium falciparum-infected whole blood sample treatment (Kemleu et al., 
2016). The NP-40 and Tween 20 detergents have been applied for naso-
pharyngeal sample treatment (Nie et al., 2012). 
Although several sample preparation techniques have been used, the search 
continues for efficient and fast lysis agents that neither interfere with down-
stream application nor require additional instrumentation, such as membrane-
active peptides, discussed below.  
 
 
1.5.3. Isothermal amplification directly from clinical samples  
There are several indications that isothermal amplification techniques are less 
sensitive towards biological sample components than conventional PCR.  
LAMP has been shown to be a relatively robust amplification technique, 
tolerating well pH variation within the range of 7.3–9.3 and addition of stool, 
urine, 10 µM hemin, 100 mM NaCl, and several anticoagulants (e.g. heparin, 
EDTA, and citrate) (Francois et al., 2011). LAMP has been also found to 
tolerate high urea concentrations of ≤1.8 M, while PCR only tolerates up to 50 
mM urea (Edwards et al., 2014, Khan et al., 1991), and to be significantly less 
sensitive towards blood components than PCR (Poon et al., 2006, Francois et 
al., 2011) as well as culture medium and other biological substances such as 
phosphate buffered saline (PBS) (Kaneko et al., 2007).  
RPA tolerates serum and hemoglobin at 50 g/l concentration; however, it is 
inhibited by whole blood (Kersting et al., 2014).  
Several researchers have addressed the issue of isothermal amplification 
directly from unprocessed or minimally processed biological samples. There is 
growing proof that the DNA extraction step can be replaced with a simple pro-
cessing procedure without significant effect on the assay’s analytical and 
clinical sensitivity.  
Proteinase K-treated Zika virus-spiked sputum, urine, and serum samples 
showed comparable sensitivity levels to extracted DNA (Wang et al., 2016). 
Triton X-100 treatment of Plasmodium falciparum-infected whole blood 
samples resulted in 85% clinical sensitivity, while extraction of the DNA 
increased sensitivity only to 90% (Kemleu et al., 2016).  
Boiling and dilution was found to be suitable pretreatment for blood or 
serum samples. 95% clinical sensitivity for Plasmodium falciparum detection 
was claimed for heat-treated blood samples (Poon et al., 2006). 92% of hepatitis 
B virus HBV-positive clinical plasma samples were detected by simple heating 
procedure (Nyan et al., 2014). Crude blood lysates prepared simply by dilution 
in water have been shown to be sufficient for highly sensitive detection of 
Plasmodium sp by LAMP (Kongkasuriyachai et al., 2017). Additionally, heat 
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treatment coupled with dilution of blood and saliva samples proved to have 
equal efficiency to DNA extraction for Plasmodium falciparum detection 
(Modak et al., 2016). 
High clinical sensitivity was detected for heat-treated respiratory samples. 
87% clinical sensitivity was observed for human enterovirus detection from 
heat-treated nasopharyngeal swab samples (Nie et al., 2012), 90.9% sensitivity 
for adenovirus (ADV) detection from nasopharyngeal aspirates (Sun et al., 
2014) and 70–80% clinical sensitivity for respiratory syncytial virus (RSV) 
detection from heat-treated respiratory samples (Hoos et al., 2017).  
Unprocessed samples have been shown to be suitable for direct amplification 
by LAMP. The analytical sensitivity of LAMP remained the same when DNA-
extracted samples were compared to direct amplification from Klebsiella 
pneumoniae-spiked clinical specimens (sputum, urine, fecal, and blood 
samples) and exceeded PCR sensitivity with the same samples by 104 times 
(Nakano et al., 2015). E. coli was also detected directly from urine samples by 
LAMP without any processing (Hill et al., 2008).  
The choice of efficient processing procedure depends on the pathogen, 
sample, and isothermal amplification type. Although the potential to forgo 
costly and labor-intense nucleic acid purification is an intriguing possibility, 
further investigation is required before putting it into practice.  
 
 
1.6. Antimicrobial peptides as pathogen cell lysing agents  
Animals and plants use antimicrobial peptides (AMPs) as a defense mechanism 
against a broad range of microbes including bacteria, fungi, viruses, protozoa, 
and archaea (Varnava et al., 2017). Many AMPs have an amphipathic structure 
in which hydrophobic and cationic amino acids are clustered into spatially 
discrete sectors. AMPs specifically target microbes based on their cellular 
membrane structure, which is clearly distinguishable for a broad spectrum of 
microbes from multicellular animals. The outer layer of bacterial membranes 
exposes hydrophobic and negatively charged phospholipids (Figure 4), which 
amphipathic AMPs bind using electrostatic and hydrophobic interactions. On 
the other hand, the outside layer of animal cell membranes usually have no 
charge, and most of the negatively charged lipids are located in the inner layer 
facing the cytoplasm (Figure 4) (Zasloff, 2002). The presence of cholesterol in 
animal membranes has been shown to reduce AMP activity due to stabilization 
of the membrane (Matsuzaki et al., 1995).  
Several models have been proposed for AMP antimicrobial activity. The 
majority of AMPs act through permeabilization and/or disruption of microbial 
membranes. AMPs interact with membranes due to their physicochemical 
properties, leading to lipid displacement and often pore formation. This leads to 
diffusion of the peptides into cell interior and/or collapsing of the membrane 
into fragments and physical disruption (or lysis) of the cell (Zasloff, 2002). The 
mechanism of action depends on the particular peptide. Magainin and melittin 
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introduce small toroidal pores into the membrane, while Cecropin P1 and MSI 
peptides use carpet or detergent mechanisms for membrane disruption (Li et al., 
2017).  
In addition to selectivity between host and microbe membranes and broad 
microbial action, AMPs have to act fast due to the short doubling time of 
bacteria (20 min in case of E. coli). Another required feature of AMPs is that 
they act through such a mechanism that bacteria cannot easily develop 
resistance to them (Matsuzaki, 1999).  
Selectivity for microbial membranes, fast membrane-disruptive mechanism, 
and broad microbial action make AMPs a potentially good target for appli-
cations in clinical sample preparation prior to pathogen NAAT. Specimen treat-
ment with membrane-active AMPs could lead to specific disruption of micro-
bial cell membranes and facilitating release of the target nucleic acids. How-
ever, positively charged AMPs may also interact non-specifically with nucleic 
acids that may interfere with downstream amplification.  
 
 
 
Figure 4. Basis of the AMP (antimicrobial peptide) membrane target specificity (based 
on (Zasloff, 2002, Matsuzaki, 1999). Basic (positively charged) amino acids of the 
AMP are shown in red and hydrophobic amino acids in green. The differences in 
bacterial and erythrocyte membrane structure that result in selectivity of the AMP 
interaction are shown.  
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1.6.1. Membrane-active AMPs: Cecropins,  
melittin, and magainins 
Linear cationic α-helical peptides such as cecropins, magainins, and melittin act 
through disruption of the microbial cell.  
Melittin, which has been isolated from honeybee venom, is a 26 amino acid 
long peptide with hydrophobic N-terminal region and predominantly hydro-
philic C-terminal region (Kreil, 1973). Melittin severely disrupts lipid mem-
branes, leading to cell lysis (Tosteson and Tosteson, 1981). In addition to wide 
scope antimicrobial properties, melittin also displays potent haemolytic activity 
(Conlon et al., 2003). Melittin is more active against Gram-positive bacteria, 
while its activity towards Gram-negative bacteria is highly sensitive to buffer 
ionic composition, probably due to the importance of the electrostatic inter-
actions of peptide binding to LPS (Moerman et al., 2002).  
Bombolitin is a component of bumblebee venom whose structure and 
activities are very similar to melittin. Bombolitins have a wide range of activity 
against both Gram-positive and -negative bacteria as well as pathogenic fungi in 
plants and erythrocytes (Argiolas and Pisano, 1985, Choo et al., 2010). 
Magainins are a class of AMPs from the skin of the frog Xenopus laevis 
(Zasloff, 1987). Magainin analogues MSI-78 and MSI-594 are very potent 
AMPs that are active against numerous bacteria, including those resistant to 
conventional antibiotics (Maloy and Kari, 1995).  
Cecropins are produced as an antibacterial response of the cecropia moth, 
with exception of cecropin P1, which was isolated from nematode within pig 
intestine (Hultmark et al., 1980, Andersson et al., 2003). Cecropins permealize 
cellular membranes to execute their antimicrobial activity towards fungi, 
viruses, Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis), and 
Gram-negative bacteria (E. coli, Salmonella typhimurium, Serratia marcescens) 
(Efimova et al., 2014, Guo et al., 2014). 
 
To relieve the burden of the STI, POC-applicable, efficient, and accurate 
diagnostics are required. Current POC tests are mainly immunoassays, which 
lack the required sensitivity and specificity. The first steps for NAAT-based 
techniques application for POC diagnostics have been taken; however, no 
instrument-free solutions have yet been introduced, mainly because of the 
unresolved issue of nucleic acid preparation prior to amplification, which 
restricts easy application of NAAT in POC settings.  
 
 
  
36 
2. AIMS OF THIS STUDY 
The main objective of the research described in this dissertation is to evaluate 
the feasibility and efficiency of isothermal nucleic acid amplification directly 
from clinical samples, with the focus on establishment of POC-applicable, fast, 
robust, and efficient technology including sample preparation prior to nucleic 
acid amplification. This includes evaluation of the analytical and clinical effect 
of direct nucleic acid amplification without prior template purification as well 
as establishment of the major factors affecting nucleic acid amplification 
directly from clinical urine samples.  
 
 Paper I: The main aim of the paper was to establish an isothermal 
amplification-based C. trachomatis diagnostics assay for pathogen diag-
nostics directly from urine samples. We aimed to develop a recombinase 
polymerase isothermal amplification-based assay for application with 
minimally processed urine samples and to evaluate its sensitivity and 
specificity both clinically and analytically.  
 
 Paper II: In this paper, we aimed to establish the major inhibiting 
components of urine samples affecting loop-mediated isothermal ampli-
fication. We aimed to evaluate the effect of DNA polymerase change on 
biological sample tolerance of the isothermal amplification.  
 
 Paper III: The main aim of the paper was to establish the applicability 
and efficiency of the antimicrobial peptide-based sample pretreatment 
technique prior to isothermal amplification. We aimed to evaluate the 
efficiency of the different sample preparation techniques prior to 
amplification directly from urine samples spiked with E. coli bacteria.  
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3. METHODOLOGICAL CONSIDERATIONS 
3.1. Selection of specific amplification target  
for C. trachomatis 
Choosing a molecular target is a crucial step in amplification-based molecular 
diagnostics assay, determining both the sensitivity and specificity of the assay. 
The optimal nucleic acid target is highly conserved within different target 
pathogen serovars/strains but has sufficient variability with closely related 
species in particular. Multicopy gene targets are usually preferred as molecular 
diagnostics targets to obtain higher sensitivity of the assay. 
For C. trachomatis-specific detection, we have selected a cryptic plasmid 
target. Several diagnostics assays for C. trachomatis detection target cryptic 
plasmid, as it has been established to be important to maintaining high virulence 
of the pathogen and is present in multiple copies per cell (Carlson et al., 2008, 
Seth-Smith et al., 2009, Pickett et al., 2005). For our amplification target, we 
have chosen a region within coding sequence 2 (CDS2) encoding pGP8 protein. 
RPA and LAMP primers were designed to recognize highly conserved region 
within CDS2 sequence (Table 3).  
Gen-Bank sequence analysis with Basic Local Alignment Search Tool 
(BLAST) confirmed conservation of C. trachomatis amplification region among 
11 C. trachomatis LGV biovar strains (serovars L1, L2, L2b, and L3; strains 
L1/224, L1/1322/p2, L1/115, L1/440/LN, L2/434/BU, L2b/UCH-1, L2b/UCH-
2, L2b/LST, L2b/Ams1, L2b/Ams2, L3/404/LN) and 25 strains from a genital 
biovar (serovars D, E, F, G, Ia, J, and K; strains E-32931, E-547, E-160, E-103, 
E-DK-20, E/CS1025/11, E/SotonE8, E/SotonE4, E/Sweden3, E/Sweden2, 
E/Bour, E-8873, F-6068, F/CS847/08, F/Sweden5, F/Sweden4, Ia/SotonIa1, 
Ia/SotonIa3, K/SotonK1, J/UW-36, D/SotonD6, D/SotonD5, D-EC, D/UW-3, 
G/SotonG1). Oligonucleotides containing sequence elements that promote 
secondary structures and primer–primer interactions or hairpins were avoided. 
GAPDH housekeeping gene was used as an intrinsic control, as urine specimens 
contain up to 105/ml human epithelial cells (Table 3) (Morimoto et al., 2003). 
 
 
3.2. Isothermal amplification and product detection 
Two isothermal amplification methods, RPA and LAMP, have been used in this 
work.  
The major benefits of RPA are its short amplification time compared to other 
isothermal amplifications and its tolerance for ambient operating temperatures. 
The optimal reaction temperature of the RPA (37–42˚C) is lower than for the 
majority of other isothermal amplifications, which makes it a good candidate 
for on-site applications. Furthermore, due to the lyophilized format, RPA 
reagents are highly stable at ambient temperatures.  
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RPA reaction was performed according to the manufacturer’s (TwistDX) 
suggestion. Amplification was initiated through addition of magnesium acetate, 
incubated at 38°C, and terminated at 50°C where required. After four minutes 
of incubation, the reaction was mixed by flicking the tube. RPA primers were 
labelled with biotin and 6-carboxyfluorescein (FAM), enabling biotin-FAM 
double-labelled product detection on the PCRD-2 lateral-flow (LF) strip.  
LF strip is a simple method for amplification product detection, allowing the 
result to be detected by the naked eye within a few minutes (Figure 5). 
 
 
Table 3. RPA and LAMP amplification regions and primers used for specific C. 
trachomatis cryptic plasmid CDS2 sequence and H. sapiens GAPDH gene detection.  
RPA C. trachomatis CDS2 amplification product (5’–3’) – 116 bp 
CCTTCATTATGTCGGAGTCTGAGCACCCTAGGCGTTTGTACTCCGTCACAG
CGGTTGCTCGAAGCACGTGCGGGGTTATTTTAAAAGGGATTGCAGCTTGT
AGTCCTGCTTGAGAG 
Primer 5’ modification Sequence (5’–3’) 
FW Biotin CCTTCATTATGTCGGAGTCTGAGCACCCT
AGGC 
RV  FAM CTCTCAAGCAGGACTACAAGCTGCAATC
CCTT 
RPA H. sapiens GAPDH amplification product (5’–3’) – 146 bp 
AAGTCAGGTGGAGCGAGGCTAGCTGGCCCGATTTCTCCTCCGGGTGATGC
TTTTCCTAGATTATTCTCTGGTAAATCAAAGAAGTGGGTTTATGGAGGTCC
TCTTGTGTCCCCTCCCCGCAGAGGTGTGGTGGCTGTGGCATGGTG 
Primer 5’ modification Sequence (5’–3’) 
FW Biotin AAGTCAGGTGGAGCGAGGCTAGCTGGCC
CGATT 
RV FAM CACCATGCCACAGCCACCACACCTCTGC
GGGGA 
LAMP C. trachomatis CDS2 amplification sequence (5’–3’) 
AATATCATCTTTGCGGTTGCGTGTCCTGTGACCTTCATTATGTCGGAGTCT
GAGCACCCTAGGCGTTTGTACTCCGTCACAGCGGTTGCTCGAAGCACGTG
CGGGGTTATTTTAAAAGGGATTGCAGCTTGTAGTCCTGCTTGAGAGAACG
TGCGGGCGATTTGCCTTAACCCCACCATTTTTCCGGAGCGAGTTACGAAG
ACAAAACCTCTTCGTTGACCGATGTACTCTTGTAGA 
Primer 5’ modification Sequence (5’–3’) 
F3 - AATATCATCTTTGCGGTTGC 
B3 - TCTACAAGAGTACATCGGTCA 
FIP Biotin TCGAGCAACCGCTGTGACGACCTTCATT
ATGTCGGAGTC 
BIP FAM GCAGCTTGTAGTCCTGCTTGAGTCTTCGT
AACTCGCTCC 
LF Biotin TACAAACGCCTAGGGTGC 
LB FAM CGGGCGATTTGCCTTAAC 
 
  
39 
 
LAMP is known for its extremely high amplification efficiency and high 
specificity, as 4–6 primers used in a reaction recognize 6–8 distinct regions of 
the target gene. In addition to that, LAMP reaction is relatively low cost, which 
is an important benefit for diagnostics application.  
LAMP reaction was performed as suggested by Eiken Chemical Co. Ltd 
(Notomi et al., 2000) at 63°C. Loop primers LF and LB were used in addition to 
B3, F3, FIP, and BIP primers to increase LAMP reaction speed and sensitivity. 
FIP and LF primers were labelled with biotin and BIP and LB primers with 
FAM so that amplification product could be detected by Amodia LF strips. Bsm 
DNA polymerase was generally used for LAMP amplification. When different 
DNA polymerases were used, LAMP reaction buffer pH, salt, Mg2+, betaine, 
and dNTP concentrations were adjusted according to the manufacturer’s sug-
gestion. Detergents (Tween 20 or Triton X-100) were added to the reaction 
where required. For SD and OmniAmp DNA polymerases, LAMP reaction 
conditions were optimized experimentally (Jevtuševskaja et al., 2017). For 
quantitative LAMP (qLAMP), product formation was monitored in real time 
using Applied Biosystems 7900HT and EvaGreen fluorescent dye. ROX was 
used as a reference dye in the qLAMP reaction.  
 
Figure 5. Schematic representation of lateral-flow strip-based amplification product 
detection.  
 
 
3.3. Analytical sensitivity and specificity  
of the diagnostics assay 
Molecular diagnostics assays are characterized using sensitivity and specificity 
values. Analytical sensitivity is the ability of the diagnostic test to detect target 
nucleic acid. Analytical sensitivity is usually expressed as the minimal 
detectable concentration of the target DNA (minimal template copy number per 
reaction required for amplification product formation), also referred to as limit 
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of detection (LOD). Analytical specificity refers to the ability of the assay to 
detect the particular target nucleic acid rather than others. 
For diagnostic assay analytical sensitivity estimation, the following template 
DNA materials were used: (i) linearized pGL3-CDS2 plasmid (pGL3-Promoter 
vector carrying the C. trachomatis cryptic plasmid-encoded gene CDS2 (Krõlov 
et al., 2014)), (ii) C. trachomatis genomic DNA (gDNA) as total DNA isolated 
from HeLa-229 cells infected with C. trachomatis serovar J strain UW-36/Cx 
(ATCC® VR-886™), and (iii) human gDNA (RNA-free DNA purified from 
cultured HeLa cells). 
Assay analytical specificity was estimated with 20–100 pg of gDNA from 
bacterial species potentially present in patient samples, such as Mycoplasma 
genitalium (ATCC 33530), Neisseria gonorrhoeae (ATCC-53422D), Urea-
plasma urealyticum (NCTC 10177), and E. coli MG16.55 gDNA, as well as 1 
ng of human gDNA.  
 
 
3.4. Clinical sensitivity and specificity  
of the diagnostics assay 
Clinical sensitivity refers to the test’s ability to correctly detect patients who 
have the condition and shows the probability of a positive test given that the 
patient has the disease. Sensitivity is calculated as follows: 
 
Sensitivity = TP/(TP + FN) (Table 4) 
 
Clinical specificity is the ability of the test to correctly identify patients who do 
not have the condition or the probability of a healthy person without the disease 
to be given a negative test result. Specificity is calculated as follows:  
 
Specificity = TN/(TN + FP) 
 
 
Table 4. Estimation of the clinical sensitivity and specificity of the diagnostic assay. 
 
Condition 
(determined by Cobas Amplicor C. trachomatis test) 
Condition positive Condition negative 
Test outcome 
Positive True positive (TP) 
False positive 
(FP) 
Negative False negative (FN) 
True negative 
(TN) 
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The sensitivity and specificity values alone can be misleading; therefore, they 
are often accompanied by a confidence interval (CI), which refers to the range 
of values within which the correct value lies at a given probability level (for 
example 95%).  
For this work, clinical specificity, sensitivity, and 95% CIs were calculated 
using the clinical calculator from VassarStats (http://www.vassarstats.net/ 
clin1.html). The reference method used for detection of C. trachomatis in 
clinical urine samples was a Roche Cobas Amplicor CT/NG test performed by 
the United Laboratories of Tartu University Hospital.  
 
 
3.5. Collection and handling of clinical samples 
Urine specimens were used for this work. Samples were collected from 70 
patients (51 females and 19 males) attending a Sexual Health Clinic (Tartu, 
Estonia) during the period of April–May 2013. Approval for the study was 
obtained from the Research Ethics Committee of the University of Tartu. 
Patients were 18–25 years old, with a mean age of 21.5 years. Patient selection 
for STI analysis was performed by clinicians based on the following criteria: 
recent change of a sexual partner, multiple partners, unprotected sexual 
intercourse, STI detected in a partner, or STI symptoms (such as increased or 
abnormal vaginal discharge, abdominal pain, or painful urination). The first-
void morning urine samples were self-collected. Mean sample volume was 25–
35 ml (varying from 15 to 45 ml). Collected specimens were stored at 4°C and 
tested by RPA within one day of collection. 
Simulated clinical samples were prepared by spiking pooled urine sample 
with E. coli DH5α-carrying pGL3-CDS2 plasmid. Bacteria was grown to mid 
logarithmic phase and washed with PBS prior to dilution in pooled urine to a 
concentration of 0.2–1×105 cells/µl. 
Pooled patient urine samples (from five males and five females tested 
negatively for C. trachomatis) were used as a sample matrix to eliminate the 
aberrant effect due to naturally occurring high heterogeneity of the clinical 
samples.  
 
 
3.6. Sample preparation prior to amplification 
Several strategies were applied for sample pretreatment prior to amplification.  
Total DNA was extracted from urine samples using the QIAamp Viral RNA 
Mini Kit (Qiagen). For heat treatment, samples were incubated 5 min at 90°C. 
For enzymatic lysis, samples were incubated for 5 min at RT°C with 1mg/ml of 
lysozyme in the presence of 1% Triton X-100 or 10 mM EDTA to enhance lysis 
efficiency for Gram-negative E. coli. For chemical lysis with mild detergent, 
samples were incubated for 5 min at RT°C in the presence of 1% Triton X-100. 
Alkaline lysis of the simulated urine samples was performed as a two-step 
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procedure, incubating samples for 5 min at RT°C with equal volume of lysis 
solution (400 mM KOH, 100 mM DTT, 10 mM EDTA) followed by 
neutralization with 400 mM HCl, 600 mM Tris HCl, pH 0.6.  
The use of antimicrobial peptides (AMPs) for sample preparation was also 
studied. Samples were treated with selected membrane-active AMPs, like 
melittin, magainin analogue MSI-78 (pexiganan), againin-melittin MSI-594, 
bombolitin III, cecropin P1, and cecropin B analogue SB-37 (Table 5) for 5 min 
at RT°C with 50 µM final peptide concentration.  
 
 
Table 5. List of the antimicrobial peptides used in the study and their sequences. 
Peptide  Sequence References 
Melittin GIGAVLKVLTTGLPALISWIKRKR
QQ-NH2 
(Kreil, 1973) 
MSI-78 GIGKFLKKAKKFGKAFVKILKK-
NH2 
(Hallock et al., 2003) 
MSI-594 GIGKFLKKAKKGIGAVLKVLTTGL
-NH2 
(Porcelli et al., 2006) 
Bombolitin III IKIMDILAKLGKVLAHV-NH2 (Argiolas and Pisano, 
1985) 
Cecropin P1 SWLSKTAKKLENSAKKRISEGIAIA
IQGGPR 
(Pillai et al., 2005) 
SB-37  MPKWKVFKKIEKVGRNIRNGIVK
AGPAIAVLGEAKALG 
(Jaynes et al., 1989, 
Jaynes et al., 1988) 
 
 
3.7. Determining main urine inhibitory  
components on LAMP 
To evaluate the effect of urine on LAMP, several potential inhibitors were 
selected and tested at different concentrations. Urine samples have varying Na+ 
ion concentrations, ranging on average from 50–190 mM. Therefore, LAMP 
efficiency was tested after addition of 5µl of 150 mM or 300 mM NaCl. Mg2+ 
ions have a direct effect on DNA polymerase activity and fidelity and therefore 
significantly affect amplification efficiency. Furthermore, Mg2+ ions affect 
annealing temperatures of several primer-template hybrids. Physiologically 
relevant Mg2+ concentration in urine ranges from 1.7–5.7 mM. We have tested 
LAMP activity in the presence of 0.1 mM, 0.5 mM, and 1 mM MgSO4. Urea is 
known to prevent non-covalent bonding acting directly on the polymerase or 
hindering primer annealing (Hedman and Rådström, 2013). Normal 
concentration of urea in urine samples is 18 mg/l (Khan et al., 1991); we have 
tested the effect of addition of 1.5 mg/l, 15 mg/l, and 30 mg/l of urea on the 
LAMP reaction. The average concentration of albumin in urine is normally 10 
mg/l but can be significantly increased in patients with conditions such as 
albuminuria. We have tested LAMP activity at BSA concentrations 0.07 mg/ml, 
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0.2 mg/ml, 0.7 mg/ml, 2 mg/ml, and 4 mg/ml. Normal urine can be slightly 
acidic or alkaline, with pH ranging on average from 4–9. Changes in pH can 
affect intermolecular bonds, and therefore enzymes are usually sensitive 
towards pH changes outside their optimal range. Therefore, addition of 5 µl of 
100 µM HCl or 1 µM NaOH on LAMP efficiency was also tested.  
 
 
3.8. E. coli membrane integrity and viability studies 
To evaluate antimicrobial activity of selected AMPs, E. coli viability was 
assessed by colony-forming units (CFUs) count. E. coli cells were briefly 
treated with 50 µM AMP, and dilution series were plated for CFU count 
assessment. Viability was evaluated as a percentage of viable cells following 
AMP treatment as compared to untreated samples. 
E. coli membrane integrity was also evaluated by flow cytometry (BD 
LSRII). The ability of propidium iodide to migrate into the E. coli cells was 
used to evaluate the cell lysis efficiency of different sample pretreatment 
techniques, such as heat, alkali, detergent, lysozyme, and treatments with 
different AMPs. 
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4. RESULTS AND DISCUSSION 
The research work described in this thesis addresses the issue of implementation 
of nucleic acid amplification-based diagnostics in POC applications. Although 
NAAT tests offer high sensitivity and specificity levels, they are difficult to 
implement in an instrument-free way. Additionally, the nucleic acid purification 
requirement prior to amplification is considered a major obstacle for NAAT 
POC application.  
In the first paper, we used isothermal amplification for C. trachomatis 
specific diagnostics from heat-treated patient urine samples. Isothermal 
amplification enables instrument-free detection of target nucleic acids and is 
considerably less sensitive towards biological sample material, allowing direct 
amplification from urine samples. In the second paper, we address the issue of 
urine sample inhibition on loop-mediated isothermal amplification, determine 
the major inhibiting components, and propose methods for overcoming the 
inhibition. The third paper addresses the requirement and efficiency of sample 
pretreatment prior to amplification. Here we also introduce a novel sample 
pretreatment method using antimicrobial peptides and compare efficiency of 
different sample pretreatments using simulated samples (E. coli-spiked urine 
samples).  
 
 
4.1. Sensitive and rapid detection of Chlamydia trachomatis 
directly from urine samples (Paper I) 
Nucleic acid purification prior to amplification significantly affects the cost and 
complexity of the diagnostics assay. Furthermore, the procedure is poorly 
applicable in POC settings. In this paper, we have developed a C. trachomatis 
diagnostics assay that allows fast and sensitive detection of pathogen directly 
from urine samples, therefore allowing forgoing of the nucleic acid purification 
step.  
For specific and sensitive C. trachomatis detection, we have chosen a new 
amplification target, a CDS2 region located on the cryptic plasmid. This target 
region is highly conserved among different C. trachomatis serovars and is 
present in multiple copies per cell. The C. trachomatis diagnostic target was 
chosen so it would also cover the Swedish plasmid variant-carrying strains 
(Seth-Smith et al., 2009). As clinical samples usually contain patient cellular 
material, a human DNA target within the GAPDH gene was chosen for the 
intrinsic control of the reaction. Intrinsic reaction control is required for 
distinguishing negative test results from invalid reactions.  
A C. trachomatis-specific target was amplified using RPA isothermal 
amplification. For fast and sensitive detection of the amplification, LF strips 
were used, which allowed naked-eye end-point result visualization within 
minutes. RPA proved to be highly sensitive, detecting as low as 50 target DNA 
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copies per reaction, which translates to 5–12 pathogen cells per analysis 
(depending on the plasmid copy number).  
3–12 min minimal reaction times have been reported for RPA depending on 
the template concentration (Wang et al., 2017). We have determined that in our 
settings, RPA reaction time could be reduced to 10 min without affecting the 
detection limit. This correlates well with previous findings that 10–12 min is the 
required time to result in RPA reactions at template concentrations near LOD. 
RPA reaction time can be reduced even to 3 min when high template DNA 
concentrations are used (Wang et al., 2017).  
We have also established that RPA can tolerate up to 10% urine in the 
reaction without significant loss of assay analytical sensitivity. Although whole-
blood has been shown to be quite inhibiting to the RPA reaction (Kersting et al., 
2014), our findings show RPA to be relatively tolerant towards urine specimens. 
Amplification was possible even when urine concentration was increased to 
20% in the RPA reaction; however, that high sample concentration was 
affecting the signal intensity on the LF strips. Thus, urine specimens are 
significantly less inhibiting to RPA reaction than to PCR (Khan et al., 1991), 
and RPA can potentially be applied directly to urine samples without prior 
nucleic acid purification.  
To our knowledge, this was the first work describing the effect of urine on 
RPA assay and attempting amplification directly from minimally processed 
clinical samples. RPA amplification from urine samples has been further 
confirmed by other researchers (Valiadi et al., 2016, Rosser et al., 2015). 
However, 10% urine was found inhibiting by (Rosser et al., 2015) at the near 
LOD template concentration. This might be explained by high heterogeneity of 
urine samples, with some specimens being more inhibiting to amplification than 
others. We have addressed this issue by using pooled specimens from ten 
different patients to reduce the aberrant effect due to sample heterogenicity.  
To confirm our analytical findings, we have performed a small-scale clinical 
study to evaluate RPA-based C. trachomatis detection efficiency directly from 
urine samples of 70 patients. Heat treatment has been shown to be a relatively 
efficient sample pretreatment technique prior to isothermal amplification 
directly from several biological samples (Nyan et al., 2014, Hill et al., 2008, 
Sun et al., 2014, Jain et al., 2011). We have heated patient urine samples for 5 
min at 90°C prior to RPA amplification. Clinical evaluation of RPA-based 
assay combined with heat treatment resulted in 83% sensitivity (95% CI, 51%–
97%) and 100% specificity (95% CI, 92%–100%). Obtained clinical sensitivity 
values are significantly higher than the average 40–60% sensitivity reported for 
C. trachomatis POC immunoassays (Yin et al., 2006, Bandea et al., 2009, 
Sabidó et al., 2009, van der Helm et al., 2012). However, nucleic acid purifi-
cation prior to RPA analysis increased clinical sensitivity values to 100% (95% 
CI, 70%–100%). Therefore, improvement of direct nucleic acid amplification 
sensitivity should be addressed by future research.  
We and others have shown direct amplification from urine samples with 
other isothermal amplification methods such as LAMP (Nakano et al., 2015, 
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Hill et al., 2008, Jevtuševskaja et al., 2016). Nakano et al. have achieved 
comparable clinical sensitivity with LAMP directly from unprocessed samples 
as compared to purified DNA samples. In our study, clinical sensitivity was 
reduced from 100% to 83% when heat-treated urine samples were used instead 
of purified DNA. Only 55% clinical sensitivity was achieved for C. trachomatis 
detection with LAMP from unprocessed samples, and 64% sensitivity for heat-
treated samples (Jevtuševskaja et al., 2017). The difference in clinical per-
formance is probably due to the different amplification methods, different target 
pathogens, and use of clinical versus simulated samples. The possibility for 
direct amplification from minimally processed clinical samples exists, although 
its reliability needs further clinical confirmation. Further studies should also 
address the need and efficiency of sample processing prior to isothermal 
amplification.  
In addition, our clinical study has confirmed previous findings concerning 
the lack of correlation between symptoms and C. trachomatis infection. Only 
25% of C. trachomatis-positive patients were symptomatic, while 26% of C. 
trachomatis negative patients also displayed symptoms that could be associated 
with the STI, emphasizing again the need for routine screening in order to 
prevent further spread of the STI.  
The major advantage of the developed diagnostics assay is its speed, as the 
whole process, including sample processing, can be completed within 15–20 
min (Figure 6). Up to 30 min performance time is generally accepted for on-
site POC diagnostics tests. The developed C. trachomatis RPA assay meets this 
requirement. In addition to being an extremely fast amplification technique, 
RPA also tolerates ambient incubation temperatures and uses lyophilized 
reagents, making it a good candidate for POC applications. With LF naked-eye 
result readout, RPA carries the potential to be applied in a completely 
instrument-free manner.  
However, the biggest advantage of the developed C. trachomatis assay is its 
high specificity and relatively high sensitivity levels. The specificity of 100% 
(95% CI, 70%–100%) greatly surpasses Gram staining and urine flow 
cytometry, and sensitivity of 83% (95% CI, 51%–97%) is far above the average 
immunoassay sensitivity, including those of Quickview, ACON, Biorad, or 
Diagnostics for the Real World rapid C. trachomatis tests. The sensitivity of the 
isothermal amplification-based POC assay can be further improved by reducing 
the inhibitory effect of the biological samples and through optimization of the 
sample pretreatment procedure. Both of these aspects will be addressed further 
in Papers II and III presented in this dissertation.  
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Figure 6. RPA-based C. trachomatis detection assay layout from sample to result. 
Urine samples were prepared for amplification by simple heating procedure. 
Recombinase polymerase amplification (RPA) was then performed directly from urine 
lysates. FAM-biotin double labelled amplification product was then detected using 
lateral-flow technology.  
 
 
4.2. Tolerance of urine and its major inhibitors by  
different DNA polymerases in loop-mediated isothermal 
amplification (Paper II) 
The inhibiting effect of biological sample components on nucleic acid ampli-
fication is a significant concern for amplification from crude biological samples 
in particular, but also because traces of inhibiting components can be present in 
purified nucleic acid samples. This can lead to reduced sensitivity of the assay 
by causing a false negative effect. We have addressed this issue by analyzing 
the effect of the urine samples and their components on LAMP isothermal 
amplification.  
There are indications that amplification inhibitors majorly affect DNA 
polymerase activity, meaning that change of the polymerase can have a 
significant effect on the assay inhibitor tolerance (Baar et al., 2011, Ghadessy et 
al., 2001, Kermekchiev et al., 2009). We have selected 11 DNA polymerases 
(Bsm, Bst, Bst2.0, Bst2.0 WarmStart, GspSSD, GspSSD2.0, GspM, GspM2.0, 
Tin, OmniAmp, and SD DNA polymerase) and analyzed their speed and urine 
tolerance in LAMP reaction.  
GspSSD2.0 polymerase was significantly faster than others with an esti-
mated time to result of only 10 min, while Tin and SD DNA polymerases were 
slowest, requiring at least 35 min. Other tested polymerases had similar speed 
ranges, achieving results in 17–25 min.  
Bsm polymerase displayed the highest tolerance towards urine, with no 
change in reaction speed even in the presence of 20% urine. Bst2.0, GspM2.0, 
and GspSSD2.0 were also able to tolerate moderately the presence of 10% urine 
in the reaction, producing results within 20 min. SD, OmniAmp, and Tin 
polymerases had the lowest tolerance towards clinical samples, and therefore 
should not be the primary choice for direct amplification. Notably, SD poly-
merase is a Taq-based mutant carrying additional strand-displacement activity. 
Taq polymerase is known to have high sensitivity towards biological samples in 
PCR reaction (Khan et al., 1991, Al-Soud and Rådström, 2001, Abu Al-Soud 
and Rådström, 2000); therefore, these results for SD polymerase could be have 
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been expected. In addition, our results confirmed that biological sample 
inhibition is majorly due to the effect on DNA polymerase activity.  
To investigate the nature of urine inhibition, we next tested LAMP ampli-
fication in the presence of several potential inhibitory components. Major 
known amplification inhibitors of urine samples are urea and high salt (K+, Na+, 
Mg2+) concentrations (Schrader et al., 2012). Urine is also known to have high 
protein content under certain conditions; thus, we have tested the effect of 
addition of the BSA to LAMP. Due to their highly heterogeneous nature, urine 
samples’ pH can vary from 4–9; therefore, we have also addressed this effect on 
LAMP.  
Addition of urea, BSA, MgSO4, alkali, or acid to the reaction (at tested 
concentrations) had no significant effect on LAMP amplification efficiency for 
any of the tested polymerases. Confirming previous findings, LAMP reaction 
proved to be significantly less sensitive towards urea addition than PCR (Khan 
et al., 1991, Edwards et al., 2014). Addition of NaCl to the reaction, on the 
other hand, had a major effect on LAMP reaction that correlated well with urine 
intolerance. Polymerases like OmniAmp, Tin, and SD were highly sensitive 
towards NaCl and urine addition to the reaction. Amplification efficiency of the 
Bsm polymerase was not affected by urine addition, nor was reaction speed 
reduced upon increased NaCl concentration.  
These findings indicate that high salt concentration in urine could be the 
main inhibiting component of LAMP. High salt concentration could act by 
influencing binding of the DNA polymerase to the template. Thus, DNA poly-
merases with stronger affinity towards the template could be less affected by 
salt addition and could possibly tolerate higher quantities of urine sample.  
It should be noted that GspM2.0 and GspSSD2.0 polymerases were quite 
sensitive towards urine addition, although their reaction speed was not affected 
by NaCl. Therefore, clinical sample inhibition of these polymerases is probably 
implemented by a different effector.  
In conclusion, our research showed that LAMP isothermal amplification is 
less sensitive towards urine sample addition than PCR, which is in accordance 
with previous findings and confirms the possibility of isothermal NAAT 
application for direct amplification from clinical samples. The selection of 
polymerase used in NAAT significantly affects speed and biological sample 
tolerance. Thus, individual amplification reaction optimization is required to 
achieve optimal results. Our findings show that GspSSD2.0 polymerase should 
be selected when the fastest time to result is required. Bsm polymerase dis-
played high tolerance towards urine sample addition to the reaction. Addi-
tionally, high Na+ concentration was found to be majorly responsible for LAMP 
inhibition; thus, omission of salt from the reaction buffer could be considered 
for direct amplification from urine samples.  
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4.3. Implementation of membrane-active antimicrobial 
peptides for sample preparation prior to isothermal 
nucleic acid amplification (Paper III) 
The finding that isothermal amplification techniques could tolerate the presence 
of biological samples in the reaction created the opportunity for direct ampli-
fication from minimally processed samples, allowing forgoing of the nucleic 
acid purification step. Although unprocessed samples can sometimes be directly 
applied for amplification (Hoos et al., 2017, Hill et al., 2008, Nakano et al., 
2015), a simple sample preparation procedure is generally required for in-
creased sensitivity of the assay (Sun et al., 2014, Nie et al., 2012, Wang et al., 
2016, Kongkasuriyachai et al., 2017).  
Heat, detergent, alkali, and enzymatic treatments have been applied prior to 
LAMP amplification (Nakanishi et al., 2011, Sun et al., 2014, Wang et al., 
2016). Several of these well-established sample pretreatment techniques have 
limitations such as low efficiency, multi-step procedure, sensitivity towards 
buffer components, instrument requirements, and inapplicability to some patho-
gen types. In this work, we have investigated the possibility of urine sample 
pretreatment with antimicrobial peptides (AMPs) prior to amplification and 
compared it to other well-established sample processing techniques.  
AMPs often act through disruption of cellular membrane on wide spectra of 
microbes such as bacteria, viruses, fungi, and protozoa. In the context of 
diagnostics, lysis of cells is important for release of the nucleic acids that are 
used as a target material for amplification. We have shown that AMPs are 
highly efficient in bacterial cell disruption in the biological sample 
environment, lysing the cells completely within 5 min incubation at RT°C. Heat 
and alkali treatment resulted in comparable cell lysis to that of AMP treatment, 
while detergent and lysozyme treatment were less effective on E. coli.  
Inhibitors of the amplification reaction are a major concern with unpurified 
samples. In addition to the inhibitors present in the biological sample, sample 
pretreatment materials can also be inhibiting to the reaction. We have es-
tablished that LAMP isothermal amplification is particularly sensitive towards 
addition of alkaline lysis components and Triton X-100. Several AMPs can bind 
nucleic acids in a non-specific manner due to the positive charge of the 
peptides. Magainin analogues (MSI-78 and MSI-594) were highly inhibiting to 
the reaction, while cecropin family peptides (Cecropin P1 and SB-37) had a 
moderate effect on LAMP amplification. 
To investigate the efficiency of different sample pretreatment techniques 
prior to LAMP amplification, we have spiked urine samples with E. coli 
bacteria. Our results showed that pretreatment of the sample was important for 
optimal amplification sensitivity. In our hands, Cecropin P1 pretreatment of 
simulated urine samples was most efficient, followed by heat treatment. Alkali 
and SB-37 pretreatment also resulted in moderate increases in the amplification 
template amount. These results correlate with clinical results of C. trachomatis 
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detection by LAMP amplification from unprocessed, heat-treated, and AMP-
treated urine samples (respective clinical sensitivity values are 55%, 64%, and 
73%) (Jevtuševskaja et al., 2016).  
These findings show the potential applicability of AMPs for biological 
sample pretreatment prior to isothermal amplification. Major advantages of 
AMP pretreatment over other conventional methods are that it is a fast, room-
temperature applicable, one-step procedure with potential applicability for a 
wide spectrum of microbes. Therefore, AMP pretreatment could be considered 
a viable candidate for POC applications.  
In general, our work has shown that sample pretreatment is required prior to 
NAAT, as it helps to release intracellularly located template nucleic acids. Effi-
cient sample pretreatment can have a significant impact on clinical and 
analytical assay sensitivity. Inhibition of sample pretreatment components on 
downstream amplification can be a concern. Further research should address 
AMP pretreatment applicability with different clinical sample materials and 
target organism types.  
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5. CONCLUSIONS 
This work evaluated a possible use of nucleic acid amplification directly from 
urine samples without prior purification of target DNA. Direct nucleic acid 
amplification was evaluated analytically using two isothermal amplification 
techniques: loop-mediated isothermal amplification (LAMP) and recombinase 
polymerase amplification (RPA). Different sample preparation methods were 
applied for sample pretreatment prior to amplification with AMP treatment to 
give the best results. Potential biological sample inhibitors were determined, 
and isothermal amplification assay condition adjusted accordingly to allow 
direct amplification from clinical samples. Direct amplification was also 
evaluated with a small-scale clinical study. Results of this work are particularly 
valuable for pathogen diagnostics in POC applications. 
The key findings from the research presented in this dissertation are listed 
below: 
 
 Paper I. In this study, we developed a POC-applicable C. trachomatis 
detection assay. We chose RPA isothermal amplification for sensitive and 
specific pathogen detection directly from heat-treated urine samples. The 
developed assay could detect as few as 5 pathogens per reaction and had 
clinical sensitivity and specificity of 83% and 100%, respectively. The 
whole procedure was fairly simple and did not require specific laboratory 
instrumentation or trained personnel, and the reaction result could be 
visualized within 20 min using lateral-flow dipstick technology.  
 Paper II. Here we evaluated the efficiency of several DNA polymerases 
for amplification directly from urine samples in LAMP isothermal 
amplification. We established the amplification speed of 11 commercially 
available polymerases and their tolerance towards urine samples and 
major inhibitory components. We found that the choice of polymerase is 
crucial for optimal speed and sensitivity of isothermal amplification 
directly from clinical samples. We also identified high salt as a major 
inhibitor present in the urine samples affecting LAMP amplification 
efficiency.  
 Paper III. In this study, we applied antimicrobial peptides for urine 
sample pretreatment prior to isothermal amplification. Using urine 
samples spiked with E. coli bacteria, we established that pretreatment 
with cecropin P1 AMP increased amplification target DNA to six times 
that of untreated urine on average. We have also evaluated heat, alkali, 
enzymatic, and detergent treatment efficiency for urine sample pretreat-
ment prior to isothermal amplification and found that AMP treatment was 
most efficient, followed by heat treatment. 
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SUMMARY IN ESTONIAN 
Nukleiinhapete amplifikatsioonil põhinev diagnostika  
otse kliinilistest proovidest Chlamydia trachomatis  
detektsiooni näitel uriini proovist 
Seksuaalsel teel levivad infektsioonid (STLI) on oluliseks koormaks tervishoiu-
süsteemile. Iga päev nakatub nendesse üle miljoni inimese maailmas. STLI-de 
diagnoosimine on keeruline, sest enamus haigusi ei põhjusta mingeid sümpto-
meid. Samas ravimata jäänud suguhaigused võivad põhjustada kroonilisi põleti-
kulisi reaktsioone ning avaldada selle kaudu olulist mõju inimese reproduktiiv-
sele tervisele. Suureks probleemiks on ka infektsioonide ülekandumine sünnita-
valt emalt lapsele ning STLI-de põhjustatud tüsistused raseduse ajal.   
Kõrgesse riskigruppi kuuluvate inimeste ja rasedate skriinimine on ennast 
tõestanud efektiivne strateegia STLI-de leviku piiramiseks ning nendega seon-
duvate tüsistuste vältimiseks. Rutiinne STLI diagnostika vajab aga usaldusväär-
seid ja kiireid lahendusi, mille puudumist peetakse peamiseks STLI-de kontrol-
limatu leviku põhjuseks. Tsentraalsetesse laboritesse koondunud diagnostika 
meetodid on suures osas automatiseeritud ning pakkuvad väga täpseid tulemusi. 
Kuid nende hind ja infrastruktuuri vajadus piirab laiahaardelist rakendamist. 
Üldlevinud arvamuse kohaselt aitab STLI-de levikut piirata ennekõike usaldus-
väärse kiirtesti olemasolu, mis võimaldab haigustekitajat diagnoosida arstivi-
siidi käigus.  
Chlamydia trachiomatis-t võib pidada levinuimaks suguhaiguste põhjusta-
jaks. Igal aastal nakatub C. trachomatis-ega ligi 130 miljonit inimest üle maa-
ilma, ning selle esinemissagedus seksuaalselt aktiivsete noorte seas võib ulatuda 
kuni 20%-ni. Praegu turul olevad C. trachomatise kiirtestid põhinevad immuno-
analüüsil ning on üsna vähe tundlikud. Piisava tundlikkuse puudumine piirab 
nende laialdasemat kasutuselevõttu.   
Antud doktoritöös esitatud teadustulemused on suunatud nukleiinhapete 
(DNA) amplifikatsioonil põhineva diagnostika rakendamisele kiirdiagnostikas. 
Kiirdiagnostika vajab ennekõike kiireid (soovitavalt alla poole tunniseid) mee-
todeid, mis võimaldavad väga täpselt ennustada patogeeni olemasolu proovis, 
soovitavalt täiesti instrumendivabalt. Klassikaline DNA amplifikatsiooni mee-
tod PCR vajab temperatuuri tsüklilist muutumist, mistõttu ei sobi hästi instru-
mendivabaks rakenduseks. Selles töös töötati välja isotermilisel amplifikat-
sioonil põhinevat C. trachomatise diagnostika meetod, mille suurimaks eeliseks 
on, et see on teostatav kasutades ainult termostaati. Väljatöötatud meetodis pii-
sab 10 minutit kestvast amplifikatsiooni reaktsioonist C. trachomatise DNA 
olemasolu tuvastamiseks kliinilisest proovist. Amplifikatsiooni produkti 
olemasolu on palja silmaga registreeritav kasutades külgvoolu immunokromato-
graafilist detektsiooni süsteemi, mis võimaldab kohest kvalitatiivse vastuse 
saamist. Võrdluseks tasub mainida, et enamus laboridiagnostika meetodeid 
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vajab vastuse saamiseks aega mitu tundi. Väljatöötatud meetodi kliiniline ana-
lüüs näitas selle sensitiivsuseks ja spetsiifilisuseks 100%.  
Lisaks potentsiaalsele instrumendivabale rakendusele on isotermilise ampli-
fikatsiooni suurimaks plussiks suurem tolerantsus bioloogiliste proovide mater-
jali suhtes. Meie juhul võimaldas see omadus viia läbi C. trachomatise DNA 
amplifikatsiooni otse uriini proovidest ilma eelneva nukleiinhapete puhasta-
miseta. Eelnevalt kuumutatud uriiniproovide kasutamine otse amplifikatsioo-
niks tagas kliinilises uuringus 83% sensitiivsuse. See on oluliselt suurem teiste 
kiirmeetoditega võrreldes, mille kliiniline sensitiivsus jääb keskmiselt 40% 
juurde.  
Võimalus vältida nukleiinhapete puhastamist enne amplifikatsiooni on väga 
suureks eeliseks kiirdiagnostika rakenduste jaoks, tehes metoodika mitte ainult 
odavamaks, vaid ka oluliselt lihtsamaks. Samas tõstatab DNA amplifikatsioon 
otse kliinilistest proovidest küsimusi, mis puudutavad nii bioloogiliste proovi-
materjalide inhibitsiooni amplifikatsioonireaktsioonile kui ka eeltöötluse vaja-
duse nukleiinhapete vabastamiseks rakkude seest.  
Meie näitasime, et isotermilised amplifikatsioonimeetodid on oluliselt tole-
rantsemad kliinilise proovimaterjali lisamise suhtes reaktsioonile kui PCR. Nii 
näiteks suudab isotermiline LAMP amplifikatsioon (loop-mediated isothermal 
amplification) töötada kuni 20% uriini juuresolekul, ilma et reaktsiooni kiirus 
oleks mõjutatud. Samuti selgus meie uuringutest, et peamiseks amplifikatsiooni 
reaktsiooni inhibiitoriks on uriini proovides sisalduv kõrge sool (Na+ ioonide 
näol). Inhibiitorite mõju avaldub peamiselt DNA polümeraasi aktiivsuse inhi-
beerimise kaudu. Selle tõttu on üheks toimivaks mehhanismiks diagnostika 
meetodi parandamiseks tolerantse DNA polümeraasi selektsioon või geneetiline 
modifikatsioon, mis selgus ka meie katsetes.  
Et suures osas asub sihtmärk DNA rakkude sees, siis üldjuhul vajavad 
kliinilised proovid töötlemist, mis võimaldaks DNA vabastamist rakkudest. Me 
võrdlesime erinevate proovi eeltöötlemise meetodite efektiivsust nagu kuumu-
tamine, aluseline töötlus ning töötlus detergendi või lüsotsüümiga. Uue stratee-
giana rakendasime membraan-aktiivseid antimikroobseid peptiide proovimaat-
riksis sisalduvate patogeeni rakkude lüüsiks. Meie tulemused näitasid, et proovi 
eeltöötlus on vajalik ning võimaldab oluliselt tõsta amplifikatsiooni efektiivsust. 
Samuti näitasime, et antimikroobsete peptiididega töötlus on võrreldud meeto-
ditest kõige efektiivsem.  
Kokkuvõtteks näitas uurimistöö amplifikatsiooni võimalikkust otse bioloogi-
lisest proovist ilma eelneva nukleiinhapete puhastamiseta adresseerides ka bio-
loogilise proovi inhibitsiooni ja eeltöötluse teemasid.  
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